Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) Sees Significant Drop in Short Interest

Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 200 shares, a decline of 90.0% from the February 29th total of 2,000 shares. Based on an average trading volume of 21,700 shares, the short-interest ratio is presently 0.0 days.

Invesco Nasdaq Biotechnology ETF Stock Performance

Shares of IBBQ traded down $0.10 during mid-day trading on Thursday, reaching $22.18. 49,579 shares of the company’s stock traded hands, compared to its average volume of 23,344. The business’s 50-day moving average price is $22.12 and its 200-day moving average price is $20.82. The stock has a market capitalization of $23.73 million, a P/E ratio of 16.48 and a beta of 0.61. Invesco Nasdaq Biotechnology ETF has a 12 month low of $18.18 and a 12 month high of $23.02.

Invesco Nasdaq Biotechnology ETF Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Investors of record on Tuesday, March 19th were issued a dividend of $0.0435 per share. The ex-dividend date was Monday, March 18th. This represents a $0.17 annualized dividend and a yield of 0.78%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IBBQ. UBS Group AG grew its holdings in shares of Invesco Nasdaq Biotechnology ETF by 259.3% during the 1st quarter. UBS Group AG now owns 1,254 shares of the company’s stock valued at $26,000 after acquiring an additional 905 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Invesco Nasdaq Biotechnology ETF by 26.6% during the 4th quarter. Bank of America Corp DE now owns 17,931 shares of the company’s stock valued at $378,000 after acquiring an additional 3,765 shares in the last quarter. Partners Capital Investment Group LLP grew its holdings in shares of Invesco Nasdaq Biotechnology ETF by 100.4% during the 2nd quarter. Partners Capital Investment Group LLP now owns 25,717 shares of the company’s stock valued at $525,000 after acquiring an additional 12,887 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Invesco Nasdaq Biotechnology ETF by 66.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 27,946 shares of the company’s stock valued at $571,000 after acquiring an additional 11,122 shares in the last quarter. Finally, Royal Bank of Canada purchased a new position in shares of Invesco Nasdaq Biotechnology ETF during the 1st quarter valued at $1,940,000.

Invesco Nasdaq Biotechnology ETF Company Profile

The Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index, a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ. IBBQ was launched on Jun 11, 2021 and is managed by Invesco.